Loading...

PODCAST

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

science life sciences

All Episodes

00:10:08

AI News: Artera presented data at #ASCO25 showing...

BiotechTV - News ·

2025/06/06

CMO Tim Showalter describes the finding, which was selected as a "Best of ASCO" oral presentation. Plus, helping to determine how certain patients and ethnic groups will respond to therapies in the real world. and what is next for Artera.

en-us

00:11:26

Kymera Therapeutics' Founder & CEO Nello Mainolfi...

BiotechTV - News ·

2025/06/04

He describes the data, which was released on Monday, and highlights the future of the program - including how we will see more data in atopic dermatitis patients by the end of the year. Plus, discussing a new target Kymera recently announced for other immuno-inflammatory diseases, IRF5.

en-us

00:11:40

ASCO 2025: PharmaMar presented data showing that the...

BiotechTV - News ·

2025/06/03

Global Product Lead José Antonio López-Vilariño describes the data and VP of Strategic Development Pascal Besman puts the result in context of this cancer type and stage that historically has had a very poor prognosis.

en-us

00:14:28

ASCO 2025: France based Transgene presented data for...

BiotechTV - News ·

2025/06/03

Chairman and CEO Alessandro Riva describes the computational work that is done to choose the personalized neoantigens for this cancer vaccine, and he describes why head and neck was a good fit to test the therapy out in. Plus, he covers the data and talks about next steps.

en-us

00:16:11

ASCO 2025: Candel Therapeutics CEO Paul Peter Tak...

BiotechTV - News ·

2025/06/02

He explains the design of the therapy, and covers the data presented at ASCO. Plus, filing and manufacturing plans, and highlighting this program in other cancers.

en-us

00:09:53

ASCO 2025: Strand Therapeutics Co-Founder & CEO Jake...

BiotechTV - News ·

2025/06/02

He explains why IL-12, and how the self-replicating aspect may be giving this more durability over first generation mRNA cancer immunotherapies. He covers the data, and describes how Strand is seeing the abscopal effect in some patients for this intra-tumoral administered product.

en-us

00:14:00

ASCO 2025: Allogene presented data today for a CD70...

BiotechTV - News ·

2025/06/02

CEO David Chang\ describes the data and explains why he believes the company's "Dagger" platform makes a difference. Plus, an update on Allogene's 1L consolidation trial in LBCL, and his thoughts on cell therapy for autoimmune diseases.

en-us

00:14:55

ASCO 2025: The leaders of Daiichi-Sankyo discuss new...

BiotechTV - News ·

2025/06/02

Global Head of Oncology Ken Keller walks us through the company's ASCO data and highlights other future catalysts to watch, which new Global CEO Hiroyuki Okuzawa discusses the company's long-term plans to be a top 10 oncology company.

en-us

00:12:20

Deerfield Management Managing Partner James Flynn...

BiotechTV - News ·

2025/06/02

He describes raising the fund, and his take on the current challenging environment in healthcare. Plus, his thoughts on AI specifically, and how Deerfield is adding new people to both participate in it and invest in it.

en-us

00:15:18

ASCO 2025: Protagonist Therapeutics' CEO Dinesh Patel...

BiotechTV - News ·

2025/06/02

He describes the Rusfertide result, which is partnered with Takeda and was presented in a plenary session at ASCO. Plus, he covers a UC announcement that JNJ made in March, and guides for when Protagonist will announce an obesity program.

en-us

00:09:08

ASCO 2025: Bicara Therapeutics' CEO Claire Mazumdar...

BiotechTV - News ·

2025/06/02

She describes Bicara's data in HPV-negative HNSCC, and explains why the company is focused on this HVP-negative population specifically. Plus, how she believes the data compares to a closely watched competitor has a EGFR x LGR5 program.

en-us

00:12:14

ASCO 2025: Legend Biotech's CEO Ying Huang discusses...

BiotechTV - News ·

2025/06/02

He describes long-term data for CARTITUDE-1 and a subset analysis from CARTITUDE-4. Plus, a DLL3 targeting armored CAR and a Claudin 18.2 program.

en-us

00:11:00

ASCO 2025: Arcus Biosciences' CEO Terry Rosen...

BiotechTV - News ·

2025/06/02

He describes the HIF-2a approach, and today's data release at ASCO, as well as why he believes Casdatifan can be best in class compared to one product that is already on the market.

en-us

00:11:26

ASCO 2025: Arvinas CEO John Houston discusses the...

BiotechTV - News ·

2025/06/01

He describes the trial's success in patients with ESR1 mutations, and discusses the steps ahead for both this program and the protein degradation field in general.

en-us

00:08:29

ASCO 2025: Novocure today announced positive overall...

BiotechTV - News ·

2025/05/31

CEO Ashley Cordova describes the idea behind tumor treating fields, and walks us through today's pancreatic cancer data. Plus, how the company's launches are going in brain and lung cancers, and preparing to file in pancreatic later this year.

en-us

00:15:21

ASCO 2025: Gilead Sciences' Chairman & CEO Dan O'Day...

BiotechTV - News ·

2025/05/31

He discusses the result of the ASCENT-04 study, which was in combination with Keytruda in PD-L1+ patients, and highlights data forthcoming at a future meeting for ASCENT-03 in PD-L1 negative patients. Plus, a brain cancer cell therapy program, Gilead's partnership with Arcus on TIGIT, and the company's deal appetite.

en-us

00:09:58

ASCO 2025: Instil Bio CEO Bronson Crouch discusses...

BiotechTV - News ·

2025/05/30

He offers what he believes are learnings from this morning's data, and describes the data Instil's partner ImmuneOnco has derived for their asset to date. Plus, plans for future data later this year and getting a U.S. study up and running.

en-us

00:19:01

Pfizer Chairman & CEO Dr. Albert Bourla discusses the...

BiotechTV - News ·

2025/05/30

Dr. Bourla looks back on Pfizers $43B acquisition of Seagen and the company's more recent license of a VEGF x PD1 bispecific. He highlights ASCO data for BRAFTOVI, vepdegestrant, and XTANDI. Plus, his thoughts on the hot button issues of China biotech and biopharma's public reputation.

en-us

00:07:27

Piper Sandler Senior Analyst David Amsellem reacts to...

BiotechTV - News ·

2025/05/29

He gives his thoughts on the competitiveness of Teva's TL1A, and highlights other pipeline programs that biotech investors might look at. Plus, how the company is doing transitioning its investor base from generic drug focused investors to biotech.

en-us

00:08:11

At Teva's Innovation & Strategy Day in New York...

BiotechTV - News ·

2025/05/29

He highlights Teva's improved financial position, its commercial prowess, and the pipeline assets to watch, including a TL1A that biotech investors have been watching closely.

en-us

486 results

Similar Podcasts

Rabbit Hole of Research

Jotham Austin, II PhD, Nick Elizalde,...

跨国串门儿计划

yikai

The Grave Talks | Haunted, Paranormal & Supernatural

Ghost Stores, Haunted, Paranormal &...

Real Ghost Stories Online

Real Ghost Stories Online | Paranormal,...

Sleep Science

Sleep Science